DMAC Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -1.12%, SMA50 -1.02%, SMA200 28.95%). The stock’s 14-day RSI is 47.68 (neutral), while the ATR of 0.49 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.01% below its high and over 157.99% above its low. Average 10-day trading volume of 228.46 thousand shares is in line with the 3-month average of 216.59 thousand, indicating normal recent market interest.

DiaMedica Therapeutics Inc. has 51.69 million shares outstanding. The public float is 27.07 million shares, elevated short interest at 11.26% of float. This equals 4.03 million shares. The short ratio is 12.13 days. Institutional investors hold 56.62% of the float. Insiders own 33.51%. STAHLBERG JAN holds 8.83 million shares, Von Koch Thomas has 8.38 million shares and JACINTO RICHARD II has 4.96 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

DiaMedica Therapeutics Inc. generated EPS of -$0.72 over the past year. Five-year average earnings growth is 7.39%. Wall Street analysts project EPS growth of -13.62% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.18. Next year's EPS is expected at -$10.50. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $10.00. The high target offers 251.12% upside. The low target suggests 40.45% downside. The mean target is $14.00. This offers 96.63% upside. DiaMedica Therapeutics Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 12, 2025, missed forecasts by 13.33%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -15.96% in August 07, 2024.

DiaMedica Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.07. This means the shares are trading above this model’s fair value.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) closed at $7.12 USD, losing -$0.04 (-0.56%) from the previous close of $7.16. The stock is currently mid-range between its 52-week high and low $3.19 and $10.42. With a market capitalization of about $370.79 million, DiaMedica Therapeutics Inc. is classified as a small-cap and shows market-like volatility (beta ~1.10). Key stats such as the average daily volume over the past year has been around 214.35 thousand shares, trading with heavier-than-usual volume. Headquartered in Minneapolis, MN, DiaMedica Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dietrich John Pauls, the company employs approximately 27 people and listed since August 03, 2012. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases.

DiaMedica Therapeutics Inc. trades at a P/E ratio of -11.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.88 trading at moderately above to book value. The P/FCF stands at -13.39, also below market averages.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) shares are flat -6.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows DiaMedica Therapeutics Inc. trading at a premium to the broader market with a P/E of -11.12. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $12.70, suggesting 78.37% upside. Our AI forecast model points to short-term weakness (-5.76% over two weeks), a medium-term fall (-41.01% over three months), and a longer-term gain (319.1% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that DiaMedica Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.76%, with price expected at $6.71 by March 31, 2026, within a range of $6.39 to $7.02 3-Month Outlook: Projected fall of -41.01%, reaching $4.20 by June 15, 2026, with a range of $4.05 to $4.34. 1-Year Outlook: Projected gain of 319.1%, with price at $29.84 by March 17, 2027, within a range of $31.33 to $31.92.